Studying the effect of duloxetine on depression and sleep in MS patients

Investigating the effect of duloxetine on depression and sleep in Multiple Sclerosispatients in Kashani hospital

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20250116064399N1

Enrollment

Registered

2025-03-18

Start date

2025-02-19

Completion date

Unknown

Last updated

2025-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Multiple sclerosis. Multiple sclerosis

Interventions

Intervention 1: Intervention: receiving duloxetine in initial doses of 30 mg per day, and after 7 days, the drug dose will be increased to 60 mg to complete the treatment for 12 weeks. It is better to

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Patients diagnosed with Multiple sclerosis Multiple sclerosis patients who have minor to moderate depression.

Exclusion criteria

Exclusion criteria: Previous use of duloxetine History of any psychiatric disorder Taking corticosteroid medications Has major depression Liver disease, kidney disease and pregnancy

Design outcomes

Primary

Measure	Time frame
Investigating the effect of duloxetine on "depressive symptoms" in MS patients. Timepoint: Before the start of the study and three months after consumption. Method of measurement: Depression questionnaire.	—

Secondary

Measure	Time frame
Study of the drug duloxetine on "sleep quality" in MS patients. Timepoint: At the beginning of the study (before the intervention) and 90 days after starting duloxetine. Method of measurement: PSQI questionnaire.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMahnaz Momenzadeh

Esfahan University of Medical Sciences

Mahnazmomenzadehf@gmail.com009836687977

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026